It has been more than five years since the first CAR-T therapies, Kymriah® and Yescarta®, received market authorisation from the FDA and the EMA as next-generation cancer treatments. How are they doing now? Despite the hefty price tags (close to half a million dollars!), their arrival still stirred up considerable global hype. That is hardly a surprise given the tremendous unmet need – reflected by the  20 million new diagnoses and 9.7 deaths cancer-attributable deaths in 2022 . Despite...